Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 10/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 9/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 9/20 | 1.00 |
| ▸ | GRIK5 | Q16478 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13957600 | 0.82 | GRIA1 (0.69) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL12648446 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL8631021 | 0.82 | GRIA1 (0.69) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL8296644 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL5000789 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL4311549 | 0.82 | GRIA1 (1.00) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL770144 | 0.76 | KMT2A (0.60) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL20088133 | 0.73 | CYP1A2 (0.57) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| (S)-Willardiine SCHEMBL438494 | 0.72 | GRIA1 (0.56) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| (S)-Willardiine SCHEMBL401191 | 0.72 | GRIA1 (0.56) | GRIA1GRIA2GRIA4GRIK5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232025-A1 | SAFENER DRUG COMBINATIONS FOR USE WITH NMDA ANTAGONIST DRUGS | OLNEY JOHN W (US) | 2012-09-13 | — | — | US | claimed |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | claimed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-11208475-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2008097546-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | COLUCID PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008088820-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | SENTION, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1689704-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | CoLucid Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005042475-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | SENTION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | disclosed |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | GRIA1 407/4885GRIA2 648/4885GRIA4 325/4885 |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | GRIA1 1432/4885GRIA2 1522/4885GRIA4 1222/4885 |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | GRIN1, GRIN2A, GRIN2B | GRIA1 21/4885GRIA2 11/4885GRIA4 23/4885 |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | ACHE, BCHE, CHAT | GRIA1 1565/4885GRIA2 1427/4885GRIA4 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.